Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

被引：0

作者：

DiNardo, C. ^{[1
]}

Stein, A. ^{[2
]}

Stein, E. ^{[3
]}

Fathi, A. ^{[4
]}

Frankfurt, O. ^{[5
]}

Schuh, A. ^{[6
]}

Doehner, H. ^{[7
]}

Martinelli, G. ^{[8
]}

Patel, P. ^{[9
]}

Raffoux, E. ^{[10
]}

Tan, P. ^{[11
]}

Zeidan, A. ^{[12
]}

de Botton, S. ^{[13
]}

Kantarjian, H. ^{[1
]}

Stone, R. ^{[14
]}

Lam, D. ^{[15
]}

Wang, X. ^{[15
]}

Gong, J. ^{[15
]}

Kapsalis, S. ^{[16
]}

Hickman, D. ^{[16
]}

Zhang, V. ^{[16
]}

Winkler, T. ^{[16
]}

Wu, B. ^{[16
]}

Vyas, P. ^{[17
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] City Hope Med Ctr, Duarte, CA USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[5] Northwestern Univ, Chicago, IL 60611 USA

[6] Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] Ulm Univ Hosp, Ulm, Germany

[8] IRST, Meldola, Italy

[9] UT Southwestern Med Ctr, Dallas, TX USA

[10] Hop St Louis, Paris, France

[11] Royal Perth Hosp, Perth, WA, Australia

[12] Yale Canc Ctr, New Haven, CT USA

[13] Inst Gustave Roussy, Villejuif, France

[14] Dana Farber Canc Inst, Boston, MA 02115 USA

[15] Celgene, Summit, NJ USA

[16] Agios, Cambridge, MA USA

[17] Univ Oxford, Oxford, England

来源：

ANNALS OF HEMATOLOGY | 2019年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

40a

引用

页码：S40 / S41

页数：2

共 50 条

[1] Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
DiNardo, Courtney D.
Stein, Anthony S.
Stein, Eytan M.
Fathi, Amir T.
Frankfurt, Olga
Schuh, Andre C.
Doehner, Hartmut
Martinelli, Giovanni
Raffoux, Emmanuel
Tan, Peter
Zeidan, Amer
de Botton, Stephane
Kantarjian, Hagop M.
Stone, Richard M.
Lam, Du
Wang, Xiwei
Gong, Jing
Kapsalis, Stephanie M.
Hickman, Denice
Zhang, Vickie
Winkler, Thomas
Daigle, Scott
Vyas, Paresh
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S217 - S218
[2] Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
Dinardo, Courtney Denton
Stein, Anthony Selwyn
Stein, Eytan M.
Fathi, Amir Tahmasb
Frankfurt, Olga
Schuh, Andre C.
Martinelli, Giovanni
Patel, Prapti Arvind
Raffoux, Emmanuel
Tan, Peter
Zeidan, Amer Methqal
de Botton, Stephane
Kantarjian, Hagop M.
Stone, Richard M.
Lam, Du Hung
Gong, Jing
Zhang, Vickie
Winkler, Thomas
Wu, Bin
Vyas, Paresh
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly- Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study
DiNardo, Courtney D.
Roboz, Gail J.
Stein, Eytan M.
de Botton, Stephane
Mims, Alice S.
Prince, Gabrielle T.
Altman, Jessica K.
Arellano, Martha L.
Donnellan, Will
Erba, Harry P.
Mannis, Gabriel N.
Pollyea, Daniel A.
Stein, Anthony S.
Uy, Geoffrey L.
Watts, Justin M.
Fathi, Amir T.
Kantarjian, Hagop M.
Tallman, Martin S.
Choe, Sung
Dai, David
Fan, Bin
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Hickman, Denice
Liu, Hua
Agresta, Samuel V.
Wu, Bin
Attar, Eyal C.
Stone, Richard M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S220 - S220
[4] Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model
Yen, Katharine
Chopra, Vivek S.
Tobin, Erica
Avanzino, Brian
Mavrommatis, Konstantinos
DiMartino, Jorge
MacBeth, Kyle J.
CANCER RESEARCH, 2018, 78 (13)
[5] Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.
Roboz, Gail J.
Dinardo, Courtney Denton
Stein, Eytan M.
de Botton, Stephane
Mims, Alice S.
Prince, Gabrielle T.
Altman, Jessica K.
Arellano, Martha Lucia
Erba, Harry Paul
Pollyea, Daniel Aaron
Stein, Anthony Selwyn
Watts, Justin M.
Fathi, Amir Tahmasb
Kantarjian, Hagop M.
Tallman, Martin S.
Fan, Bin
Liu, Hua
Wu, Bin
Attar, Eyal C.
Stone, Richard M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.
Pollyea, Daniel Aaron
Dinardo, Courtney Denton
de Botton, Stephane
Stein, Eytan
Roboz, Gail J.
Mims, Alice S.
Swords, Ronan T.
Altman, Jessica K.
Collins, Robert
Mannis, Gabriel N.
Uy, Geoffrey L.
Donnellan, William Bruce
Pigneux, Arnaud
Fathi, Amir Tahmasb
Liu, Hua
Wu, Bin
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine
Daigle, Scott R.
Choe, Sung
Quek, Lynn
DiNardo, Courtney D.
Stein, Anthony
Stein, Eytan M.
Fathi, Amir T.
Frankfurt, Olga
Schuh, Andre C.
Kantarjian, Hagop M.
Zhang, Vickie
Winkler, Thomas
Vyas, Paresh
Wu, Bin
BLOOD, 2019, 134
[8] Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
DiNardo, Courtney D.
Stein, Eytan M.
de Botton, Stephane
Roboz, Gail J.
Altman, Jessica K.
Mims, Alice S.
Swords, Ronan
Collins, Robert H.
Mannis, Gabriel N.
Pollyea, Daniel A.
Donnellan, Will
Fathi, Amir T.
Pigneux, Arnaud
Erba, Harry P.
Prince, Gabrielle T.
Stein, Anthony S.
Uy, Geoffrey L.
Foran, James M.
Traer, Elie
Stuart, Robert K.
Arellano, Martha L.
Slack, James L.
Sekeres, Mikkael A.
Willekens, Christophe
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Yang, Hua
Dai, David
Fan, Bin
Goldwasser, Meredith
Liu, Hua
Agresta, Sam
Wu, Bin
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S204 - S205
[9] Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
DiNardo, Courtney D.
Stein, Anthony S.
Stein, Eytan M.
Fathi, Amir T.
Frankfurt, Olga
Schuh, Andre C.
Dohner, Hartmut
Martinelli, Giovanni
Patel, Prapti A.
Raffoux, Emmanuel
Tan, Peter
Zeidan, Amer M.
de Botton, Stephane
Kantarjian, Hagop M.
Stone, Richard M.
Frattini, Mark G.
Lersch, Frederik
Gong, Jing
Gianolio, Diego A.
Zhang, Vickie
Franovic, Aleksandra
Fan, Bin
Goldwasser, Meredith
Daigle, Scott
Choe, Sung
Wu, Bin
Winkler, Thomas
Vyas, Paresh
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (01) : 57 - +
[10] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Popovici-Muller, Janeta
Lemieux, Rene M.
Artin, Erin
Saunders, Jeffrey O.
Salituro, Francesco G.
Travins, Jeremy
Cianchetta, Giovanni
Cai, Zhenwei
Zhou, Ding
Cui, Dawei
Chen, Ping
Straley, Kimberly
Tobin, Erica
Wang, Fang
David, Muriel D.
Penard-Lacronique, Virginie
Quivoron, Cyril
Saada, Veronique
De Botton, Stephane
Gross, Stefan
Dang, Lenny
Yang, Hua
Utley, Luke
Chen, Yue
Kim, Hyeryun
Jin, Shengfang
Gu, Zhiwei
Yao, Gui
Luo, Zhiyong
Lv, Xiaobing
Fang, Cheng
Yan, Liping
Olaharski, Andrew
Silverman, Lee
Biller, Scott
Su, Shin-San M.
Yen, Katharine
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305

← 1 2 3 4 5 →